Estonia - Tiếng Estonia - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 25mg 0.5ml 0.5ml 14tk; 25mg 0.5ml 0.5ml 4tk; 25mg 0.5ml 0.5ml 6tk; 25mg 0.5ml 0.5ml 15tk; 25mg 0.5ml 0.5ml 12tk; 25mg 0.5ml 0.5ml 10tk; 25mg 0.5ml 0.5ml 2tk; 25mg 0.5ml 0.5ml 11tk; 25mg 0.5ml 0.5ml 1tk

Estonia - Tiếng Estonia - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 12,5mg 0.25ml 0.25ml 4tk; 12,5mg 0.25ml 0.25ml 15tk; 12,5mg 0.25ml 0.25ml 11tk; 12,5mg 0.25ml 0.25ml 5tk; 12,5mg 0.25ml 0.25ml 24tk; 12,5mg 0.25ml 0.25ml 1tk; 12,5mg 0.25ml 0.25ml 14tk; 12,5mg 0.25ml 0.25ml 10tk; 12,5mg 0.25ml 0.25ml 6tk; 12,5mg 0.25ml 0.25ml 12tk

Estonia - Tiếng Estonia - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 17,5mg 0.35ml 0.35ml 6tk; 17,5mg 0.35ml 0.35ml 1tk; 17,5mg 0.35ml 0.35ml 15tk; 17,5mg 0.35ml 0.35ml 24tk; 17,5mg 0.35ml 0.35ml 10tk; 17,5mg 0.35ml 0.35ml 2tk; 17,5mg 0.35ml 0.35ml 12tk; 17,5mg 0.35ml 0.35ml 5tk; 17,5mg 0.35ml 0.35ml 4tk; 17,5mg 0.35ml 0.35ml 11tk

Estonia - Tiếng Estonia - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 20mg 0.4ml 0.4ml 1tk; 20mg 0.4ml 0.4ml 5tk; 20mg 0.4ml 0.4ml 11tk; 20mg 0.4ml 0.4ml 10tk; 20mg 0.4ml 0.4ml 4tk; 20mg 0.4ml 0.4ml 6tk; 20mg 0.4ml 0.4ml 2tk; 20mg 0.4ml 0.4ml 15tk; 20mg 0.4ml 0.4ml 14tk; 20mg 0.4ml 0.4ml 12tk

Estonia - Tiếng Estonia - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 10mg 0.2ml 0.2ml 11tk; 10mg 0.2ml 0.2ml 14tk; 10mg 0.2ml 0.2ml 4tk; 10mg 0.2ml 0.2ml 2tk; 10mg 0.2ml 0.2ml 24tk; 10mg 0.2ml 0.2ml 10tk; 10mg 0.2ml 0.2ml 1tk; 10mg 0.2ml 0.2ml 15tk

Estonia - Tiếng Estonia - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 15mg 0.3ml 0.3ml 4tk; 15mg 0.3ml 0.3ml 2tk; 15mg 0.3ml 0.3ml 10tk; 15mg 0.3ml 0.3ml 6tk; 15mg 0.3ml 0.3ml 14tk; 15mg 0.3ml 0.3ml 12tk; 15mg 0.3ml 0.3ml 24tk; 15mg 0.3ml 0.3ml 15tk; 15mg 0.3ml 0.3ml 5tk; 15mg 0.3ml 0.3ml 11tk

Estonia - Tiếng Estonia - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 7,5mg 0.15ml 0.15ml 6tk; 7,5mg 0.15ml 0.15ml 24tk; 7,5mg 0.15ml 0.15ml 10tk; 7,5mg 0.15ml 0.15ml 11tk; 7,5mg 0.15ml 0.15ml 2tk; 7,5mg 0.15ml 0.15ml 5tk; 7,5mg 0.15ml 0.15ml 12tk; 7,5mg 0.15ml 0.15ml 14tk; 7,5mg 0.15ml 0.15ml 4tk; 7,5mg 0.15ml 0.15ml 1tk

Estonia - Tiếng Estonia - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 22,5mg 0.45ml 0.45ml 14tk; 22,5mg 0.45ml 0.45ml 1tk; 22,5mg 0.45ml 0.45ml 10tk; 22,5mg 0.45ml 0.45ml 2tk; 22,5mg 0.45ml 0.45ml 11tk; 22,5mg 0.45ml 0.45ml 12tk

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - leflunomiid - artriit, reumatoidartriit - selektiivsed immunosupressandid - leflunomiidi on näidustatud ravi täiskasvanud patsientidel:aktiivse reumatoidartriidi kui "haigust moduleeriva reumavastased uimasti" (dmard). hiljutine või samaaegne ravi hepatotoxic või haematotoxic dmards e. metotreksaat) võib põhjustada suurenenud risk raskete kõrvaltoimete, seega algatamise leflunomiidi ravi on hoolikalt tuleb kaaluda seoses nimetatud kasu / riski aspekte. lisaks sellele üleminek leflunomiidi teise dmard ilma pärast washout menetluse võib suureneda ka risk tõsiste kõrvaltoimete isegi pikka aega pärast lülitus.